CTOs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Precision Life Sciences

RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...

Formulated Solutions

Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.

Physician Partner

Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.